Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of human umbilical cord mesenchymal stem cells to preparation of drug for preventing and/or treating OA (osteoarthritis)

A technique for stromal stem cells and osteoarthritis, which is applied in the application field of human umbilical cord mesenchymal stem cells in the preparation of drugs for preventing and/or treating osteoarthritis, and can solve the problem of limited number of sampling and chondrocyte expansion and decreased cell proliferation ability. , Unable to repair damaged cartilage and other problems, to achieve the effect of strong cell differentiation, improvement of symptoms, and quick results

Inactive Publication Date: 2019-02-26
TIANJIN CHANGHE BIOLOGICAL TECH
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The main purpose of the surgery is to improve the biological force line of the lower limbs, eliminate the cause, improve the local blood supply, reduce the intraosseous pressure around the diseased joint, remove the diseased cartilage, and stabilize the joint. However, surgical treatment can only relieve the symptoms caused by arthritis and cannot repair it. damaged cartilage
The earliest cell therapy technology used to treat OA is autologous chondrocyte transplantation. Its advantage is that the use of its own cells reduces immunogenicity, has a high success rate, and has been approved by the FDA. The disadvantage is that the two operations increase the pain of the patient. The number of chondrocyte expansion is limited, and the ability of cell proliferation decreases with age, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of human umbilical cord mesenchymal stem cells to preparation of drug for preventing and/or treating OA (osteoarthritis)
  • Application of human umbilical cord mesenchymal stem cells to preparation of drug for preventing and/or treating OA (osteoarthritis)
  • Application of human umbilical cord mesenchymal stem cells to preparation of drug for preventing and/or treating OA (osteoarthritis)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] Embodiment 1 osteoarthritis model establishment

[0082] 6 rats of 8-week-old inbred strain sprague Dawley (SD) male rats after adaptive training were anesthetized by intraperitoneal injection of Avertin injection, the anesthesia dose was 2.5g / mg, fasting before anesthesia 12h. After anesthesia, an incision was made along the medial edge of the patellar ligament on both knee joints. After opening the joint cavity, the anterior cruciate ligament was cut off, and the posterior cruciate ligament was preserved. The wound was closed and sutured. The flow chart of establishing the rat osteoarthritis model is as follows: figure 1 shown.

Embodiment 2

[0083] Example 2 Method for treating osteoarthritis with human umbilical cord mesenchymal stem cells

[0084] Cell injection: 4 weeks after the establishment of the osteoarthritis rat model in Example 1, Avertin injection was anesthetized by intraperitoneal injection, and the human umbilical cord mesenchyme obtained by the culture method of the present invention was injected into the left knee joint cavity Stem cell injection 100μL (1×10 7 cells / mL, PBS). At the same time, rats that had not been treated with human umbilical cord mesenchymal stem cells were used as the experimental control group.

[0085] Rat knee joint sampling: 4 weeks after injection of human umbilical cord mesenchymal stem cell injection, the 2 SD rats were killed by asphyxiation and bilateral knee joint specimens were collected.

[0086] Knee joint decalcification treatment: Take out the tissue soaked in 4% paraformaldehyde solution, place it in 10% EDTA phosphate buffered saline (PBS) for decalcificati...

Embodiment 3

[0088] Example 3 Detection of Human Umbilical Cord Mesenchymal Stem Cells Treating Osteoarthritis

[0089] The gross specimens of SD rat knee joints were as follows: Figure 2A-Figure 2B As can be seen from the figure, Figure 2A The control ratio (i.e. operation side, Operation) and Figure 2B The knee joints treated with MSCs after surgery (MSCs side, Operation-MSCs) had varying degrees of damage, but the damage in the control group was more severe than that in the MSCs side.

[0090] Histological observations such as image 3 Shown, wherein, a is the HE staining result of the comparative example; b is the HE staining result of the MSCs treatment example; c is the Toluidine Blue staining result of the comparative example; d is the Toluidine Blue method (Toluidine Blue) of the MSCs treatment example Staining results; e is the Masson test result of the comparative example; f is the Masson test result of the MSCs treatment case.

[0091] Panoramic scanning results of knee j...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of biology and particularly provides an application of human umbilical cord mesenchymal stem cells to preparation of a drug for preventing and / or treatingOA (osteoarthritis). According to the application of the human umbilical cord mesenchymal stem cells to preparation of the drug for preventing and / or treating OA, the human umbilical cord mesenchymalstem cells are prepared through separation with a specific method, have little immunological rejection, low heterologous pollution and high cell differentiation capacity, effectively improve OA symptoms, reduce damage to articular cartilage, repair cartilage tissue, take effect quickly, are safe and effective and can cure OA fundamentally.

Description

technical field [0001] The present invention relates to the field of biotechnology, in particular to the application of human umbilical cord mesenchymal stem cells in the preparation of drugs for preventing and / or treating osteoarthritis. Background technique [0002] Osteoarthritis (Osteoarthritis, OA) is a chronic progressive bone joint disease, due to aging, obesity, strain, trauma, congenital abnormalities of joints, joint deformities and many other factors caused by the degeneration of articular cartilage damage, joint edges and cartilage Reactive hyperplasia of the lower bone. OA is more common in the elderly, and its incidence increases with age. It is a degenerative disease characterized by chronic progressive cartilage destruction and new bone formation. Osteoarthritis is a chronic and progressive joint disease that leads to an imbalance in the degradation and synthesis of chondrocytes, extracellular matrix, and subchondral bone under the joint action of mechanical...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/28A61P19/02A61P19/08A61P29/00A61P19/04C12N5/0775
CPCA61K35/28A61P19/02A61P19/04A61P19/08A61P29/00C12N5/0665C12N2501/11C12N2501/115
Inventor 王秀娟牟春琳徐永胜李伟
Owner TIANJIN CHANGHE BIOLOGICAL TECH